Letrozole Fempro Tablets USP 2.5 Mg

Q1: What is Letrozole (Fempro) used for?

Letrozole is a third-generation aromatase inhibitor used to treat hormone receptor-positive (HR+) breast cancer in postmenopausal women — as first-line advanced disease treatment, adjuvant therapy post-surgery, and extended adjuvant therapy following 5 years of tamoxifen.

Q2: How does Letrozole work against breast cancer?

Letrozole potently and selectively inhibits the aromatase enzyme (CYP19A1), which converts androgens to estrogens in peripheral tissues. This reduces plasma estrogen by up to 98%, depriving HR+ cancer cells of the estrogen needed for growth.

Q3: How does Letrozole compare to Anastrozole and Exemestane?

All three are third-generation aromatase inhibitors with similar efficacy. Letrozole achieves the greatest estrogen suppression (~98%). Clinical trials (BIG 1-98) have shown letrozole to be equivalent to anastrozole in adjuvant settings.

Q4: How is Fempro 2.5mg taken?

Take one 2.5mg tablet once daily, with or without food, at a consistent time each day. Treatment is continuous without scheduled breaks unless directed by your oncologist.

Q5: How long is Letrozole treatment continued?

Adjuvant treatment is typically 5 years. Extended adjuvant treatment (following tamoxifen) may continue for an additional 5 years. For advanced disease, treatment continues until progression or unacceptable toxicity.

Q6: What are the most common side effects?

Hot flashes, arthralgia (joint pain), fatigue, increased sweating, nausea, and mild peripheral edema are most common. Joint symptoms are experienced by a significant proportion of patients.

Q7: What serious side effects require monitoring?

Bone fractures (due to osteoporosis), cardiovascular events, severe allergic reactions, and liver problems (jaundice, dark urine) require prompt medical attention.

Q8: How does Letrozole affect bone density?

Letrozole reduces bone mineral density by suppressing estrogen. DXA bone scans are recommended at baseline and every 1–2 years. Calcium, vitamin D, and bisphosphonate therapy may be needed to protect bones.

Q9: Can Letrozole be taken by premenopausal women?

Letrozole is only approved for postmenopausal women. Premenopausal women can use it only in combination with confirmed ovarian suppression (via GnRH agonist). Standalone use in premenopausal women is not approved.

Q10: What drugs interact with Letrozole?

Estrogen-containing medications (HRT, oral contraceptives) counteract Letrozole and are contraindicated. Strong CYP3A4 inducers (rifampicin) may reduce Letrozole plasma levels. Tamoxifen should not be used concurrently.

Q11: Is Letrozole safe during pregnancy?

No. Letrozole is contraindicated during pregnancy and is only indicated for postmenopausal women. It may cause fetal harm and should not be used by women of childbearing potential without confirmed postmenopausal status.

Q12: Is a prescription required for Fempro?

Yes. Letrozole is a prescription-only oncology medication. It requires oncologist prescribing and periodic monitoring of bone density, lipid levels, and cardiovascular risk.